Skip to content
Yog Pharma
Central nervous systemAtypical antipsychotic

Quetiapine Fumarate is an atypical antipsychotic indicated for schizophrenia, bipolar disorder and, as extended release, adjunctive treatment of major depressive disorder. We supply it to US manufacturers of tablets and extended-release tablets.

CAS111974-72-2883.1 g/molC46H54N6O8S2
2D structure of Quetiapine Fumarate, shown as the active moiety without counter-ion or water of hydration.

Data from PubChem (CID 5281025) and FDA’s substance registry

CAS number

111974-72-2

Molecular formula

C46H54N6O8S2

Molecular weight

883.1g/mol

FDA UNII

IUPAC name

bis(2-[2-(4-benzo[b][1,4]benzothiazepin-6-ylpiperazin-1-yl)ethoxy]ethanol);(E)-but-2-enedioic acid

InChIKey

ZTHJULTYCAQOIJ-WXXKFALUSA-N

Appearance
White to off-white crystalline powder.
Solubility
Moderately soluble in water.

Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.

Worth settling with your inquiry

Supplied as the hemifumarate, two quetiapine molecules to one of fumaric acid. Strengths are expressed as quetiapine base.

On the US market

Reference product
SeroquelNDA 020639
Approved ANDAs
25 with a marketed product
Approved forms and strengths
  • Tablet 25 mg to 400 mg, in 7 strengths
  • Extended-release tablet 50 mg, 150 mg, 200 mg, 300 mg, 400 mg

Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. Strengths of salt forms are stated as the active moiety. The brand name belongs to its owner and identifies the reference product only.

Grade

USP or Ph. Eur. where a monograph exists, or your own specification.

Quantities

From development quantities for formulation work to commercial supply.

Packaging

To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.

Regulatory filings

US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.

Documents available with a quote

  • Specification and certificate of analysis
  • Safety data sheet
  • Method of analysis
  • DMF letter of authorization, where a US DMF is filed
  • GMP certificate and inspection history of the site
  • Residual solvents and elemental impurities statements
  • Nitrosamine risk assessment
  • TSE/BSE statement

Need something else for your QA file? Email info@yogpharma.com